1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Moberg Pharma AB

Moberg Pharma AB

11.10
SEK
0.00
(0.00%)
-0.45EPS
442.56MMarket Cap
Nov 12Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
68.84
79.53
89.59
114.7
132.03
143.43
1.49
- -
- -
0.02
- -
0.26
0.29
0.36
Basic EPS, GAAP
21.92
-5.74
5.49
10.26
12.9
3.65
6.48
-6.8
1.16
-1.38
-1.33
-6.74
-0.58
-0.46
Free Cash Flow per Basic Share
5.41
-17
3.98
-5.29
-275.91
11.15
-3.18
-21.7
-7.22
-7.46
-9.91
-2.38
-1.3
-0.52
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
93.84
96.44
123.84
141.27
183.62
180.3
191
- -
63.43
36.2
21.84
14.71
14.15
14.05
Tangible Book Value per Share
11.72
9.42
35.63
36.69
-143.44
-139.52
-141.54
- -
15.64
8.51
2.81
8.16
6.73
6.42
Basic Weighted Avg Shares
2
2
2
2
3
3
3
3
6
11
16
38
47
47
Sales/Revenue/Turnover
112
157
200
286
334
439
5
- -
- -
- -
- -
10
14
17
Operating Margin (%)
10.21
-9.08
5.98
10.39
4.54
8.49
-785.22
- -
- -
-9,911.59
- -
-3,311.46
-206.8
-119.54
Depreciation Expense
1
6
8
11
16
38
37
3
3
3
2
301
2
2
Net Income, GAAP
36
-11
12
26
33
11
20
-20
7
-16
-21
-255
-27
-22
Effective Tax Rate (%)
- -
- -
25.99
26.12
29.81
4.41
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
31.84
-7.22
6.13
8.94
9.77
2.54
435.71
- -
- -
-7,589.37
- -
-2,600.25
-201.18
-128.96
Working Capital
41
8
65
74
146
160
156
- -
89
101
49
283
222
208
LT Debt
28
17
3
- -
589
592
594
- -
1
4
3
3
1
- -
Total Equity
178
201
304
353
562
552
594
- -
434
534
611
687
665
663
Return on Invested Capital (%)
- -
- -
4.63
7.67
5.78
4.25
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
4.8
7.65
6.18
4.02
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
28.09
-5.98
4.86
7.78
7.14
2
3.46
- -
- -
-3.25
-3.69
-39.32
-4.03
-3.22

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
47
47
47
Market Capitalization
483
485
443

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
238
235
226
Cash, Cash Equivalents & STI
230
222
212
Accounts Receivable, Net
2
7
10
Inventories
4
6
4
Total Current Liabilities
16
18
18
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-3.14%
Free Cash Flow
534.14%
13.12%
-32.6%
Net Income, GAAP
55.49%
121.4%
-89.32%
Sales/Revenue/Turnover
- -
- -
37.99%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
4
4
1
10
2025
4
4
4
2
14
2026
5
6
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.23
-0.13
-0.03
-5.21
-6.74
2025
-0.06
-0.16
-0.09
-0.27
-0.58
2026
-0.03
-0.07
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Anna Ljung
Full Time Employees
5
Sector
Health technology
Industry
Pharmaceuticals: major
Address
GustavslundsvAegen 42 Bromma AB Sweden 167 51
IPO Date
May 26, 2011
Website
mobergpharma.se
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Moberg Pharma AB (publ) (MOB.ST) develops, manufactures, and commercializes proprietary topical pharmaceutical products focused on dermatological treatments, primarily for onychomycosis (nail fungus). The company's core product is MOB-015, a terbinafine-based cutaneous solution approved in 13 European countries and marketed as Terclara, an over-the-counter medicine that has achieved market leadership in Sweden with a 47% value share and in Norway with a 37% value share as of the third quarter of 2025; MOB-015 leverages patented formulation technology to deliver high concentrations of the antifungal agent through the nail, demonstrating 76% fungal cure rates in Phase 3 trials involving over 800 patients. Moberg Pharma operates in the specialty pharmaceuticals segment, targeting patients with mild to moderate nail fungus in consumer healthcare channels such as pharmacies, with geographic focus on Europe (including launches in Sweden since spring 2024 and Norway since February 2025), Canada, Israel, and plans for further expansion. Founded in 2006 and headquartered in Bromma, Sweden, the company was formerly known as Moberg Derma AB (publ) until its name change in May 2013. In November 2025, Moberg Pharma entered an exclusive license agreement with Karo Healthcare for MOB-015/Terclara in 19 European markets, including all major EU countries and the UK, under the Lamisil brand; Karo Healthcare assumes responsibility for marketing, distribution, and sales, while Moberg Pharma supplies product and receives royalties, marking a strategic shift toward scalable European growth without building local sales organizations. Earlier in 2025, the company raised SEK 336 million through a targeted rights issue (TO 2) and directed share issue to strengthen its balance sheet ahead of commercialization; additional partnerships include Cipher Pharmaceuticals for Canada, Allderma for Scandinavia, and Padagis for Israel. These developments support Moberg Pharma's goal to establish MOB-015 as the global market leader in nail fungus treatment, with patent protection through 2032 in key markets including the US, EU, Japan, Canada, and China.